end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableCurrent,AccruedLiabilitiesAndOtherLiabilities,AccruedProfessionalFeesCurrent,AccumulatedOtherComprehensiveIncomeLossNetOfTax,AdditionalPaidInCapital,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AllocatedShareBasedCompensationExpense,Assets,AssetsCurrent,AssetsNoncurrent,CashAndCashEquivalentsAtCarryingValue,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect,ComprehensiveIncomeNetOfTax,DebtConversionConvertedInstrumentAmount1,DebtConversionOriginalDebtAmount1,DeferredOfferingCosts,EarningsPerShareBasicAndDiluted,EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations,EmployeeRelatedLiabilitiesCurrent,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized,FairValueLiabilitiesLevel1ToLevel2TransfersAmount,FairValueLiabilitiesLevel2ToLevel1TransfersAmount,FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3,FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3,ForeignCurrencyTransactionGainLossBeforeTax,GeneralAndAdministrativeExpense,IncomeTaxExpenseBenefit,IncreaseDecreaseInAccountsPayable,IncreaseDecreaseInAccruedLiabilities,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,InterestExpense,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInInvestingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NetIncomeLossAvailableToCommonStockholdersBasic,NonoperatingIncomeExpense,OperatingExpenses,OperatingIncomeLoss,OperatingLeaseExpense,OtherAccruedLiabilitiesCurrent,OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,OtherNoncashIncomeExpense,OtherPrepaidExpenseCurrent,PaymentsOfStockIssuanceCosts,PaymentsToAcquirePropertyPlantAndEquipment,PrepaidExpenseAndOtherAssetsCurrent,ProceedsFromConvertibleDebt,ProceedsFromIssuanceOfConvertiblePreferredStock,ProfitLoss,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,ShareBasedCompensation,StockholdersEquity,StockIssuedDuringPeriodValueNewIssues,TemporaryEquityDividendsAdjustment,ValueAddedTaxReceivableCurrent,WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2021-09-30,2021-12-17,10-Q,"IO Biotech, Inc.",IOBT,CIK0001865494,USD,2166000.0,3344000.0,1445000.0,705000.0,1602000.0,,483000.0,52038000.0,51993000.0,45000.0,45477000.0,45477000.0,,-5143000.0,,,2413000.0,-36.88,,538000.0,5300000.0,0.0,0.0,,,17000.0,2914000.0,,,,,67000.0,33786000.0,52038000.0,33786000.0,,,,-4462000.0,-6535000.0,2580000.0,7042000.0,-7042000.0,81000.0,350000.0,-681000.0,,,362000.0,,,6516000.0,,,,4128000.0,-84972000.0,,-82637000.0,,2073000.0,407000.0,177200.0
